Literature DB >> 1279212

Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography.

T Inaba1.   

Abstract

Prostatic blood flow was measured with 15oxygen-water by positron emission tomography using a 1-compartment model. A dynamic study method was applied to 9 normal subjects, 6 with benign prostatic hypertrophy (BPH) and 11 with advanced stages C to D2 prostatic adenocarcinoma. Prostatic blood flow was 15.7 +/- 7.5 ml. per minute per 100 gm. in normal controls, 17.7 +/- 5.2 ml. per minute per 100 gm. in BPH patients and 29.4 +/- 7.8 ml. per minute per 100 gm. in prostatic cancer patients. Prostatic blood flow negatively correlated well with age in the normal subjects. Prostatic blood volume was also estimated by the steady state method using 15oxygen-carbon monoxide. Prostatic blood volume was 8.1 +/- 2.6% in normal controls, 8.9 +/- 1.1% in BPH patients and 6.1 +/- 2.1% in prostatic cancer patients. Blood flow in the prostatic cancer tissue was higher than that in the normal (p < 0.001) or BPH (p < 0.01) tissue. A significant difference in prostatic blood volume was also observed between BPH and cancer tissues (p < 0.02).

Entities:  

Mesh:

Year:  1992        PMID: 1279212     DOI: 10.1016/s0022-5347(17)36939-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Non-invasive quantification of tumor blood flow in prostate cancer using 15O-H2O PET/CT.

Authors:  Lars P Tolbod; Maria M Nielsen; Bodil G Pedersen; Søren Høyer; Hendrik J Harms; Michael Borre; Per Borghammer; Kirsten Bouchelouche; Jørgen Frøkiær; Jens Sørensen
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

Review 2.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

3.  11C-Choline Pharmacokinetics in Recurrent Prostate Cancer.

Authors:  Milan Grkovski; Karem Gharzeddine; Peter Sawan; Heiko Schöder; Laure Michaud; Wolfgang A Weber; John L Humm
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

4.  Comparison between population average and experimentally measured arterial input function in predicting biopsy results in prostate cancer.

Authors:  Ran Meng; Silvia D Chang; Edward C Jones; S Larry Goldenberg; Piotr Kozlowski
Journal:  Acad Radiol       Date:  2010-01-13       Impact factor: 3.173

5.  Investigation of factors affecting hypothermic pelvic tissue cooling using bio-heat simulation based on MRI-segmented anatomic models.

Authors:  Yuting Lin; Wei-Ching Lin; Peter T Fwu; Tzu-Ching Shih; Lee-Ren Yeh; Min-Ying Su; Jeon-Hor Chen
Journal:  Comput Methods Programs Biomed       Date:  2015-07-13       Impact factor: 5.428

6.  Feasibility of measuring prostate perfusion with arterial spin labeling.

Authors:  Xiufeng Li; Gregory J Metzger
Journal:  NMR Biomed       Date:  2012-06-07       Impact factor: 4.044

7.  The impeded diffusion fraction quantitative imaging assay demonstrated in multi-exponential diffusion phantom and prostate cancer.

Authors:  Dariya I Malyarenko; Scott D Swanson; Sean D McGarry; Peter S LaViolette; Thomas L Chenevert
Journal:  Magn Reson Med       Date:  2021-11-14       Impact factor: 4.668

8.  Reproducibility of tumor blood flow quantification with 15O-water PET.

Authors:  Martin A Lodge; Heather A Jacene; Roberto Pili; Richard L Wahl
Journal:  J Nucl Med       Date:  2008-10       Impact factor: 10.057

9.  Biodegradable intraprostatic doxorubicin implants.

Authors:  Ronnie Ortiz; Jessie L-S Au; Ze Lu; Yuebo Gan; M Guillaume Wientjes
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

10.  Susceptibility weighted imaging: a new tool in the diagnosis of prostate cancer and detection of prostatic calcification.

Authors:  Yan Bai; Mei-Yun Wang; Yan-Hong Han; She-Wei Dou; Qing Lin; Ying Guo; Wei Li; De-Gang Ding; Jian-Ping Dai; Wei Qin; Da-Peng Shi; Jie Tian; Yong-Ming Dai
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.